News

Hill Dermaceuticals, Inc. Launches Consumer Line

Hill has remained true to its commitment to dermatology and skin health. The foundation of Hill’s prescription dermatology products are its vehicles, also known as product base formulations without any active medication ingredients. Our vehicles contain refined peanut oil and have been shown to keep moisture in the skin, supporting the effectiveness of Hill’s prescription […]

Read Article

Why Do We Use Refined Peanut Oil?

You might be wondering why we use refined peanut oil in many of our products.  The reason is that refined peanut oil contains two essential fatty acids — linoleic acid and alpha-linolenic acid — which have been shown to (1) improve the skin’s barrier functionality and (2) help maintain appropriate hydration of the skin1,2. Typically, […]

Read Article

Pierre Fabre and Hill Dermaceuticals, Inc. announce a strategic commercial partnership for TOLAK® (fluorouracil) Cream 4% in the USA and beyond

* TOLAK is a patented prescription dermatologic drug developed by Hill Dermaceuticals for the topical treatment of actinic keratosis, a skin disease with increasing prevalence worldwide due to the combined effect of sun damage and population aging. * Pierre Fabre, a leading pharmaceutical company in dermatology, acquired commercialization rights for TOLAK in the USA and […]

Read Article

Hill Dermaceuticals, Inc.® Opens an Alternate Facility

Sanford, Florida, January 09, 2017 – Hill Dermaceuticals, Inc®, a privately held pharmaceutical company with 6 NDAs and that develops and manufactures prescription drugs focusing on Dermatologic diseases, announced the opening of its second location.  Hill’s new facility houses both offices, and alternate manufacturing suites for future projects.

Read Article

Hill Dermaceuticals, Inc® Announces FDA Orphan Drug Designation in Fungal Otitis Externa (Otomycosis)

Sanford, Florida, May 22, 2014 – Hill Dermaceuticals, Inc®, a privately held pharmaceutical company with 6 NDAs and that develops and manufactures prescription drugs focusing on Dermatologic diseases, announced that the United States Food and Drug Administration (“FDA”) has granted orphan drug designation to its investigational drug for Fungal Otitis Externa (Otomycosis).

Read Article